1. Scrip
  2. >>Business
  3. >>Financing

Poseida's CAR-T, Gene Therapy Programs Get $142m Boost, Including Novartis Cash

 
• By Mandy Jackson

Despite its sidetracked IPO, a registrational trial for the company's BCMA-targeting CAR-T is underway to support a late 2020 BLA filing and this new VC funding could accelerate additional programs. CAR-T pioneer Novartis is strictly an investor in the Series C round, but takes a board seat.

New financing should help Poseida accelerate its timeline

Poseida Therapeutics Inc. may have one of the first BCMA-targeting chimeric antigen receptor T-cell (CAR-T) therapies approved in the US for multiple myeloma, which is why investors were eager to invest in the initial public offering the company proposed in January. But when the IPO was waylaid by the US government shutdown, other options for funding its development programs emerged.

San Diego-based Poseida believes its technology lends itself to safer and more persistent CAR-T therapies. The firm closed a $142m...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Financing

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By Manas Mishra

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 
• By Andrew McConaghie

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.

Finance Watch: Two New Venture Capital Funds Provide $600m For Biopharma

 
• By Mandy Jackson

Private Company Edition: Catalio raised more than $400m for its fourth health care-focused VC fund, while AN Venture Partners raised $200m for Japan and beyond. In VC financings, among a dearth of mega rounds, Neuron23’s $96.5m series D is the largest round in recent weeks.

Actithera Raises $75m To Enter Competitive FAP-Targeting Radioligand Field

 
• By Andrew McConaghie

While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.

More from Business

Takeda Prepares Ground For Oveporexton In Narcolepsy

 
• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By Kevin Grogan

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Merck & Co’s Verona acquisition; venture funding plummets in Q2; how Teva is expanding innovation; Apogee’s Phase II eczema win; and a look at India’s wave of licensing.